INVO Fertility (IVF)
NASDAQ:IVF
Want to see IVF full AI Analyst Report?
Top Page
INVO Fertility
(NASDAQ:IVF)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▲(61.29% Upside)
Action:Reiterated
Date:06/05/26
The score is primarily weighed down by weak financial performance—large ongoing losses and worsening negative cash flow imply continued reliance on external capital. Technicals also reflect a weak longer-term downtrend with negative MACD and price below key moving averages. A Nasdaq compliance issue adds event-driven risk, while valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Proprietary ART technology and clinic network
INVOcell is a distinct intravaginal culture approach combined with direct clinic operations. This integrated product-plus-service model creates durable differentiation versus pure-play clinic chains, giving the company proprietary tech to drive patient demand and captive channels for recurring treatment revenue and upsell.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow signals the business cannot self-fund operations or investments. Deteriorating cash generation increases dependence on external capital, heightens dilution and refinancing risk, and constrains the company’s ability to invest in clinic expansion or commercial initiatives long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ART technology and clinic network
INVOcell is a distinct intravaginal culture approach combined with direct clinic operations. This integrated product-plus-service model creates durable differentiation versus pure-play clinic chains, giving the company proprietary tech to drive patient demand and captive channels for recurring treatment revenue and upsell.
Read all positive factors
INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.64M
Dividend YieldN/A
Average Volume (3M)8.28M
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth4.73%
EPS Growth43.41%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-112.91
Shares Outstanding1,786,035
10 Day Avg. Volume24,408,967
30 Day Avg. Volume8,279,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.06
Price to Sales (P/S)0.06
P/FCF Ratio-0.06
Enterprise Value/Market Cap2.46
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit3.27
Enterprise Value/Ebitda-2.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$10.42M
INVO Fertility Business Overview & Revenue Model
Company Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was establi...
How the Company Makes Money
null...
INVO Fertility Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.84M | 6.53M | 3.02M | 822.20K | 4.16M |
| Gross Profit | 2.53M | 2.87M | 1.09M | -28.57K | 4.02M |
| EBITDA | -3.51M | -7.14M | -6.88M | -10.75M | -5.22M |
| Net Income | -23.32M | -9.10M | -8.03M | -10.89M | -6.65M |
Balance Sheet | |||||
| Total Assets | 20.22M | 46.45M | 18.51M | 3.71M | 10.47M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 741.40K | 232.42K | 90.14K | 5.68M |
| Total Debt | 3.40M | 9.90M | 6.30M | 2.27M | 2.12M |
| Total Liabilities | 13.00M | 33.70M | 17.61M | 4.69M | 3.16M |
| Stockholders Equity | 7.22M | 12.75M | 892.83K | -977.61K | 7.31M |
Cash Flow | |||||
| Free Cash Flow | -7.06M | -3.16M | -5.20M | -6.62M | -6.48M |
| Operating Cash Flow | -7.01M | -2.97M | -4.76M | -6.60M | -6.03M |
| Investing Cash Flow | -2.75M | 363.89K | -2.49M | -81.22K | -2.15M |
| Financing Cash Flow | 11.10M | 3.12M | 7.39M | 1.09M | 3.77M |
INVO Fertility Technical Analysis
Negative
0.93
Price Trends
1.82
Negative
3.39
Negative
11.95
Negative
Market Momentum
-0.13
Negative
42.94
Neutral
23.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.82, and below the 200-day MA of 11.95, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 23.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.
INVO Fertility Risk Analysis
INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
INVO Fertility Peers Comparison
UnderperformOutperform
Sector (51)
IVF
INVO Fertility
1.48
-156.92
-99.07%
NIVF
NewGenIvf Group
0.56
-413.44
-99.86%
INVO Fertility Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
INVO Fertility Addresses Nasdaq Compliance Notice and Disclosure
Negative
Apr 29, 2026
On April 23, 2026, INVO Fertility, Inc. received a Nasdaq notice that it was not in compliance with listing rules after failing to timely file its Form 10‑K for the year ended Dec. 31, 2025, a delay the company attributed to the need for add...
Regulatory Filings and ComplianceStock Split
INVO Fertility Announces 1-for-5 Reverse Stock Split
Neutral
Apr 1, 2026
INVO Fertility, Inc., a Nasdaq-listed fertility services provider operating four U.S. clinics and marketing its INVOcell-enabled intravaginal culture technology, has implemented a 1-for-5 reverse stock split of its common shares. The move affects ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.